Trials / Completed
CompletedNCT02297386
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
Phase I Trial Of [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Male
- Age
- 21 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for \[18F\] Dihydro-Testosterone), to better find and monitor prostate cancer. Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen by the PET scanner. FDHT is a radiotracer that looks for a protein which is present in almost all prostate cancer cells. The investigators want to find out if we can find and monitor changes in cancer using a FDHT PET scan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F] DIHYDRO-TESTOSTERONE | |
| DEVICE | PET scan | |
| DEVICE | MRI | |
| OTHER | Blood draw |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2014-11-21
- Last updated
- 2018-08-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02297386. Inclusion in this directory is not an endorsement.